The rest of this guide explains why that answer has to be a range rather than a threshold, what moves the number, which other hormones are read beside it, and what a high or mid-range value may reflect at different ages.
Follicle stimulating hormone is made by the pituitary gland and tells the ovaries to recruit and mature follicles. As fewer follicles are available to respond, the pituitary signals harder, and the circulating level climbs. FSH is measured from a standard blood draw, reported in mIU/mL, and read against the laboratory's own reference intervals, which differ by cycle phase, age and menopausal status.
The biomarker page covers what the test measures, how the sample is collected and how a result is reported in detail. This guide stays on one question only, which is what level points toward menopause, and why the honest answer is never a number standing alone.
There is no universal cut-off, which is why the real answer is a range plus context. Most laboratories publish a separate postmenopausal reference interval that begins well above the premenopausal range, commonly somewhere around 25 to 30 mIU/mL on many assays, and extends into the tens or low hundreds after the final period. Two laboratories can report the same sample differently because they run different assay platforms and calibrate against different standards, so the interval printed next to your result matters more than any figure quoted online. A laboratory medicine review of estradiol, progesterone, luteinising hormone and follicle stimulating hormone makes the point that these results are interpreted together with menstrual history, age and assay specifics rather than against one fixed number 1.
So a value that lands inside a lab's postmenopausal interval, in a woman of the expected age who has gone twelve consecutive months without a period, fits the pattern of menopause. The same value in a 43-year-old who still bleeds irregularly fits the pattern of the menopause transition instead, where the number can rise one month and settle the next. A single high reading in a woman in her twenties or thirties is a reason for careful repeat testing and a clinical conversation, not a conclusion drawn on the spot.
Three things decide what your number means: your age, what your cycles have been doing over the past year, and what the rest of the panel shows. The hormone is one input of three, and it is the least informative of them when it is read alone. That is also why a lab report will never say menopause next to a number. It reports a value and an interval, and a clinician does the interpreting.
Menopause is defined clinically, not biochemically. The accepted definition is twelve consecutive months without a menstrual period, with no other explanation for the absence of bleeding, which means the diagnosis is made looking backwards rather than from a blood test taken today. Perimenopause is the stretch before that point, when cycles shorten, lengthen, skip and return, and symptoms often start while bleeding is still happening.
Bloodwork plays a supporting role in that picture. It is most useful when the clinical history is ambiguous: when periods have stopped for another reason, when symptoms appear unusually early, when the uterus has been removed and cycle tracking is impossible, or when something in the history suggests the pituitary or thyroid is involved rather than the ovaries. In a woman in her early fifties with classic symptoms and a year without bleeding, a blood test rarely changes what happens next.
That ordering explains a frustration many people run into. A result can sit in the postmenopausal interval while periods are still arriving, and a result can sit in the premenopausal interval in someone who has not bled for ten months. Neither outcome is a laboratory error. It reflects the fact that the number tracks pituitary signalling in the moment, while the definition tracks a full year of ovarian behaviour.
Because the feedback loop between the ovaries and the pituitary becomes erratic before it becomes quiet. In a settled reproductive cycle, follicles produce estradiol and inhibin, which damp down pituitary output and keep the hormone inside a predictable band. As the follicle pool thins, that damping signal becomes inconsistent. Some cycles still recruit a responsive follicle and produce plenty of estradiol, which pulls the number back down. Other cycles do not, and the pituitary pushes harder.
The practical result is month to month variability that can be large enough to cross a reference interval in either direction. The laboratory medicine literature makes the same practical point from the bench side, which is that results from different cycle phases are not directly comparable 1.
That is the core reason a single value cannot date menopause. One blood draw samples one week of an unstable system. A reading of 38 mIU/mL in March and 14 mIU/mL in June, in the same woman, is a familiar perimenopausal pattern rather than a contradiction. Clinicians get far more from the trend across two or three draws, taken at comparable points, than from one high number treated as a verdict.
A reference interval describes what is usual for the population the lab measured, which is not the same as what is ideal for one person. The figures below are typical adult values for context. They vary by lab, age and sex, and laboratories publish separate intervals for the follicular phase, the mid-cycle surge, the luteal phase and the postmenopausal state.
| Reading | Range | What it describes |
|---|---|---|
| Typical lab reference range | 1 to 15 mIU/mL | A general adult interval reported by many laboratories, before cycle phase is taken into account |
| FitScript optimal range | 1.5 to 10 mIU/mL | An optimisation target, narrower than the population interval |
| Postmenopausal interval | Set by each lab, commonly starting around 25 to 30 mIU/mL and extending much higher | The band labs regard as consistent with a postmenopausal state |
Optimal ranges are FitScript's optimisation targets, not diagnostic cut-offs. Reference ranges vary by laboratory, age and sex, so always compare your value with the interval printed on your own report rather than one quoted elsewhere.
Two cautions about the table. First, the general adult interval is a blunt instrument in a menstruating woman, because the same value can be entirely expected on day 3 and unexpected on day 21. Second, an elevated result does not become a diagnosis by crossing the top of a band. It becomes a finding worth interpreting alongside estradiol, age and twelve months of cycle history.
A high value means the pituitary is signalling hard, and the menopause transition is only the most common reason for that. The same pattern can appear when the ovaries have been removed or affected by surgery, radiotherapy or certain cancer therapies. It can appear in primary ovarian insufficiency, where ovarian function declines earlier than expected, and in some chromosomal and genetic conditions that affect ovarian development. Rarely, a pituitary problem can raise gonadotrophins directly.
Age is what separates these possibilities. In a woman of typical menopausal age with a year of absent periods, an elevated result is unsurprising. In a woman in her twenties or thirties, the same number is a flag for a structured work-up rather than a conclusion, because the implications for bone, cardiovascular health and fertility are different and because other causes need ruling in or out first. Repeat testing, usually on a separate occasion, is a normal part of that process.
There is also an assay explanation worth knowing. The laboratory medicine review of these hormones notes that measurement interference and assay differences can distort a result, which is one reason an unexpected value is checked before it is acted on 1. If a number does not fit the clinical picture, the first question a careful clinician asks is whether the number is right, not whether the patient is unusual.
Whatever the reason, a result that sits far outside the expected range for your age is worth discussing with a clinician promptly. It is not something to shrug off, and it is not something to self-interpret from a reference table.
Because symptoms and pituitary signalling do not move in lockstep, and because several things can hold the number down. Hot flushes, disrupted sleep, mood changes and cycle irregularity can all be well underway while the hormone is still bouncing in and out of the premenopausal band. In early perimenopause especially, a mid-range value is common and tells you very little on its own.
Medication is the other frequent explanation. Any prescribed product containing or acting on sex hormones can suppress pituitary output, so the result reflects the medication as much as the ovaries. The same applies to some conditions and treatments that act on the pituitary itself. A licensed provider is the person who decides whether testing is informative in that situation, and whether anything should change before a sample is drawn.
There are also non-ovarian reasons for absent or irregular periods that keep the hormone low or mid-range: significant energy deficit or weight loss, heavy training loads, high physiological stress, thyroid disorders and raised prolactin among them. In people with these patterns, the pituitary signal is suppressed rather than driven up, which is the opposite of the menopausal pattern and a completely different clinical path.
The practical takeaway is that a mid-range number does not close the conversation. It redirects it toward cycle history, estradiol, thyroid markers and prolactin, and toward the symptoms themselves, which are treated as real whatever the hormone says.
Several ordinary variables, and knowing them stops a lot of needless worry. The biggest is timing within the cycle, since the hormone has a predictable follicular baseline and a mid-cycle peak that can double a value without anything being wrong. In a woman still cycling, a sample taken on an unknown day is hard to interpret and sometimes has to be repeated.
Other influences worth knowing:
None of these makes the test unreliable. They make it a measurement that needs context, like most hormone measurements. The fix is standardising the conditions, repeating when a value surprises, and reading the result inside a panel rather than alone.
In a woman who is still having periods, the conventional window is early in the cycle, around days 2 to 5 of bleeding, because that is the baseline against which most follicular reference intervals are set. In a woman whose periods have stopped altogether, timing no longer applies and the sample can be taken on any day. Morning draws are common for hormone panels and make repeat comparisons cleaner.
Frequency depends on the question being asked. A single draw is often enough when the clinical picture is already clear and the test is confirmatory. When the picture is ambiguous, or when the result is unexpected for the woman's age, repeating after several weeks is the standard approach, because it separates a one-off reading from a sustained pattern. Tracking the same marker on the same platform over time is more informative than one number from one day.
Preparation is simple. Note the date of your last period, note any supplements and prescribed products, and try to keep the conditions similar between draws. If the sample is part of a broader panel, some of the other markers may have their own fasting or timing requirements, so follow the instructions for the panel as a whole.
A result is only as good as the context recorded with it. A number with no cycle date and no medication list is a number that may have to be repeated.
Follicle stimulating hormone is almost never read alone, because its meaning comes from the company it keeps. The markers below are the ones commonly grouped with it when the question is where someone sits in the menopause transition.
| Marker | What it adds to the picture |
|---|---|
| Estradiol | The main ovarian oestrogen. Read with FSH it shows whether a high signal is meeting a weak ovarian response |
| Luteinising hormone | The other gonadotrophin. The pattern between the two helps distinguish ovarian from pituitary causes |
| Anti-Mullerian hormone | Reflects the remaining follicle pool and is relatively stable across the cycle |
| TSH | Thyroid dysfunction can mimic or overlap with menopausal symptoms and affect cycles |
| Prolactin | Raised prolactin is a recognised reason for absent periods that is unrelated to menopause |
| Progesterone | Timed correctly, it indicates whether ovulation occurred in that cycle |
A grouped panel also saves repeat draws, since several of these are best measured from the same sample at the same point in the cycle. Beyond the reproductive markers, bone, metabolic and cardiovascular markers are often reviewed in the same period of life, because the transition is when several of those trajectories change at once.
The long-standing explanation for bone loss around menopause is falling oestrogen, but work on the pituitary hormone itself suggests it may act on bone cells directly. Studies suggest that follicle stimulating hormone can stimulate osteoclast formation and activity through its own receptor pathway, which would make it a contributor to bone turnover rather than a bystander 3.
The observational picture points in a similar direction. Higher FSH is associated with measures of lower bone mass and higher bone turnover in studies that looked for an explanation beyond oestrogen deficiency alone 4. A broader review of the hormone's actions on bone, fat and brain tissue describes the same theme, which is a hormone with effects in tissues well outside the ovary 5.
What this does not mean is that a high number predicts a fracture, or that the value can substitute for a bone density scan. What it does mean is that the years when the number climbs are a sensible time to pay attention to bone: resistance training, adequate protein, vitamin D and calcium status, and a conversation with a clinician about whether bone density assessment is appropriate for you.
A study of postmenopausal women reported a relationship between follicle stimulating hormone levels and metabolic syndrome, adding to a literature that treats the hormone as metabolically relevant rather than purely reproductive 6. A systematic review and meta-analysis examining the same hormone and diabetes in postmenopausal women likewise found a relationship between the two that the authors interpret cautiously 7.
Mechanistic work offers a possible explanation. Reviews of the hormone's extragonadal actions describe effects relevant to adiposity, bone and the cardiovascular system during the menopausal transition, which would link the hormonal shift to several of the changes women notice in this decade 8. Research suggests that this metabolic circuitry is part of why the transition involves more than a change in cycles 2.
The practical reading is modest and worth stating plainly. None of this makes the hormone a metabolic risk test, and none of it means a number predicts a metabolic condition in an individual. It is a reason to look at the metabolic panel in the same window, since fasting glucose, HbA1c, insulin, lipids and body composition are the markers that actually describe metabolic status, and they are measurable alongside the hormone panel from the same visit.
Mood and cognitive changes are common during the transition, and the hormone is being studied as more than a timing marker for them. Research suggests that follicle stimulating hormone may be relevant to women's mental health during the menopausal transition, through pathways distinct from oestrogen alone 9. A review of the hormone's actions on bone, fat and brain tissue describes receptor-mediated effects in the brain that would be consistent with that idea 5.
A blood value does not explain anyone's mood, and nobody should read a number as the cause of how they feel. Sleep disruption, vasomotor symptoms, life stress, thyroid status and iron status all sit in the same picture and are all measurable or treatable in their own right.
Brain fog, low mood, anxiety and poor sleep during this window are worth raising with a clinician, who can look at the hormone panel in the context of everything else and decide what, if anything, is appropriate for you.
Read it in three steps, in order. First the observation: what the number is, what units it is in, and where it sits against the interval printed on your own report. Second the meaning: what that value may reflect given your age, your cycle history over the past twelve months, and the estradiol and other markers drawn at the same time. Third the next step: what, if anything, is worth raising with a clinician.
A worked example. A value of 48 mIU/mL in a 53-year-old who last bled fourteen months ago, with a low estradiol on the same draw, fits the postmenopausal pattern and usually confirms what the history already suggested. The same 48 mIU/mL in a 44-year-old with irregular but continuing periods fits the menopause transition, where the number may be lower next time. The same 48 mIU/mL in a 31-year-old is a finding that deserves prompt clinical review and repeat testing, because the differential is wider and the implications are different.
Notice what none of those readings do. None of them label the person with a condition, and none of them turn a number into a diagnosis. That restraint is the whole discipline of reading hormone results well. A biomarker narrows the possibilities and sets the next question. The clinician, with the full history in front of them, answers it.
Always, when a result surprises you, and especially in these situations. Periods stopping before the age of 45, and certainly before 40. Any elevated gonadotrophin result in your twenties or thirties. Symptoms that are disrupting sleep, work or relationships, whatever the number says. Bleeding that is unusually heavy, unusually frequent, or that returns after twelve months without a period, which always warrants assessment regardless of hormone results. A result that does not fit your clinical picture at all, which may simply need repeating.
Bring the context with you, not just the number: the date of your last period and how cycles have changed, your symptoms and when they started, everything you take including supplements, and any previous results on the same marker. That history is what turns a value into useful information.
This page is educational and is not medical advice. Discuss your results and any treatment decisions with a clinician or licensed provider, who evaluates whether any therapy is appropriate for you based on your full history and examination.
Related reading: the menopause hormone panel groups this marker with estradiol, luteinising hormone and the thyroid markers usually read beside it, libido for menopause covers one of the symptoms women most often raise in this window, and for the same interpret-in-context logic applied to a very different marker, see what level of eosinophils indicate cancer.
Not on its own. A high result means the pituitary is signalling hard, which happens during the menopause transition but also for other reasons, especially at younger ages. Menopause is confirmed after twelve consecutive months without a period, so the blood value supports the picture rather than settling it. A clinician reads it with your age and cycle history.
Each laboratory sets its own postmenopausal interval, and on many assays it starts somewhere around 25 to 30 mIU/mL and extends much higher. Because platforms and calibration differ, compare your value with the interval printed on your own report rather than a figure quoted elsewhere, and read it together with your age and symptoms.
Yes. During the transition the value can move in and out of the premenopausal band from month to month, so a mid-range number does not rule anything out. Symptoms and cycle history carry more weight than one draw. Prescribed products that contain or act on sex hormones can also hold the number down, which your clinician will factor in.
If you are still having periods, the usual window is early in the cycle, around days 2 to 5 of bleeding, because most reference intervals are set against that baseline. If periods have stopped completely, timing no longer applies and any day works. Note the date of your last period so the lab result can be read in context.
Often, yes. Because the value swings during perimenopause, one reading samples a single week of an unstable system. Repeating after several weeks separates a one-off number from a sustained pattern, and it is standard practice when a result is unexpected for your age or does not match your clinical picture.
No. It describes the current pituitary signal, not a countdown. No single hormone value predicts the date of a final period, and prediction tools that exist rely on age, cycle patterns and repeated measurements rather than one number. Tracking your cycles over time gives a clinician more to work with.
Usually, yes. The pair together is far more informative than either alone, because a high signal next to a low ovarian output describes a different situation than a high signal next to an ordinary one. Luteinising hormone, anti-Mullerian hormone, TSH and prolactin are often grouped with them for the same reason.
That is worth raising with a clinician promptly rather than managing on your own. Periods stopping earlier than expected has a wider range of possible explanations and different implications for bone and cardiovascular health, so it generally prompts a structured assessment with repeat testing and a full history rather than a single blood draw.